
What is AIM's mission?
About 30% of all annual cancer patient deaths are due to cancers of the digestive tract. This figure is the highest in Japan and the world. Most cancers are curable if detected early, but if detected late, they can be fatal.Endoscopy is the only test that can definitively diagnose cancer of the digestive tract at an early stageBy utilizing AI, AIM aims to save lives of patients around the world by improving testing accuracy and promoting early detection of cancer.

Japan's Position in Endoscopic Medicine
In endoscopic medicine, Japan is the birthplace and world leader. Therefore, the data accumulated in Japan is among the highest in the world in terms of both quality and quantity. Therefore,The endoscopic AI developed with the wisdom of Japanese endoscopists has the potential to compete well in the global market.

Collaboration with SoftBank Group
With this financing, AIM, with the cooperation of the SoftBank Group, will deploy endoscopic AI, which is the culmination of the wisdom of Japanese endoscopists, around the world. For the future, AIM intends to deploy the endoscopic AI initially on-premise, and in the future, as a cloud platform. If endoscopic AI can be deployed in the cloud, everyone in the world will be able to receive state-of-the-art endoscopic care, which is expected to lead to early detection of cancer and a reduction in deaths.
Global Development of Endoscopic AI

AIM's policy with this financing
1. Accelerate global business
→Promoting joint research and product development with medical institutions in the U.S., Asia, etc.
→Æ Acquire talented engineers to promote global expansion.
2. Realization of a cloud platform to eradicate gastrointestinal cancers worldwide
→Build a platform to link endoscopy laboratories around the world with AI in the cloud.
Kentaro Matsui, Managing Partner, SoftBank Investment Advisers Comments
We greatly share AIM's noble vision of "further advancement of Japan's world-leading endoscopic medicine" and "saving the precious lives of cancer patients around the world. SVF, together with other SoftBank Group companies, hopes to contribute to the acceleration of AIM's growth and global expansion. We look forward to working with the Softbank Group companies to help accelerate AIM's growth and global expansion.
Comments by Yasuyuki Imai, Representative Director, Executive Vice President and COO, SoftBank Corp.
Last year, AIM and AIM jointly conducted a demonstration experiment utilizing 5G². With this investment from SoftBank Vision Fund 2, we hope to further deepen the partnership between the two companies and promote medical DX in Japan. We hope that the collaboration between AIM and SoftBank will bring this vision closer to reality, and that the development of endoscopic medicine will help patients around the world.
Comment from Mr. Satoshi Fukushima, Director, Globis Capital Partners
I am pleased that AIM, led by CEO Tada, will be able to expand from Japan to the world in earnest with stronger supporters, and I will support AIM more than ever with a strong sense of confidence and mission for the future that the world-first technology from Japan, built by AIM, will save many patients' lives on a global scale.
WiL, LLC. Co-Founder and General Partner Masanao Matsumoto Comments
We believe that AIM's use of its technology to solve medical problems and issues that are not confined to Japan will lead to even more advanced development of endoscopic medicine in Japan, a country that leads the world. I am confident that the company's goal of "saving patients around the world" will be realized. We are pleased to be able to support this project again.
Yusuke Murata, General Partner, Incubate Fund Comments
AIM has sounded the gun for global expansion.
I believe it will save the lives of many patients around the world.
We hope that this round will result in a shortening of the timeline for its realization, if only by a little.
Mr. Tomohiro Tada, CEO, AI Medical Service Comments
Japan is the birthplace of gastrointestinal endoscopic medical devices, and Japanese manufacturers account for 98% of the world market share of soft gastrointestinal endoscopes in Japan, Olympus, Fujifilm, and Pentax. The skills of Japanese gastrointestinal endoscopists are among the best in the world, and more than 17 million high-quality endoscopic examinations are performed annually in Japan. Therefore, Japanese endoscopic AI is a new global innovation created from world-class teacher data in both mass and quality.
We have conducted joint research with more than 100 top medical institutions in Japan, including Cancer Institute Hospital Ariake, and have published dozens of world-first papers, including the world's first successful research and development of AI for Pylori gastritis identification, gastric cancer detection, and esophageal cancer detection, making us a world leader in endoscopic AI research and development. We believe that if endoscopic AI, an innovation originating in Japan, can be developed globally with the support of SOFTBANK, it will contribute to the development of endoscopic medicine worldwide and will significantly increase the number of cancers detected in their early stages, saving the lives of many patients around the world. This large-scale procurement has allowed us to raise the stage of our activities to the global level. We will continue to make progress and continuous improvement and spread our wings to the world.
About AI Medical Services
AIM is a medical AI startup company established with the mission of "Saving the world's patients - to achieve zero missed cancer cases with endoscopic AI". Japan is at the forefront of endoscopic medicine, and has accumulated the world's highest quality and quantity of data. Among them, AIM is conducting joint research and product development with more than 100 medical facilities, and AIM aims to reduce the number of missed cancer cases and save patients around the world by bringing endoscopic AI to the medical field as quickly as possible.
| name of company | AI Medical Service Co. |
| Establishment | September 1, 2017 |
| Location | 11F HarezaTower, 1-18-1 Higashi-Ikebukuro, Toshima-ku, Tokyo 170-0013, Japan |
| representative | Tomohiro Tada |
| Business Overview | Development of AI (Artificial Intelligence) to support diagnostic imaging of endoscopes |
| uniform resouce locator | https://ai-ms.com/ |
comment
¹ Cumulative investment in SVF1 and SVF2 from inception to December 2021
(Adapted from SoftBank Group Corp. investor presentation material for the third quarter of the fiscal year ending March 31, 2022)
²Related Press Release: 5G Demonstration of Endoscopy AI https://www.ai-ms.com/20210326/468/









